References
- Pinkel D. Five year follow up of “total therapy” of childhood lymphocytic leukemia. JAMA 1971; 216: 648–652
- Schmiegelow K. Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1991; 8: 301–312
- Report to the Council by the Working Party on Leukaemia in Childhood. Improvement in treatment for children with acute lymphoblastic leukaemia: the Medical Research Council UKALL trials 1972-84. Lancet 1986; i: 408–411
- Smith SD, Rosen D, Trueworth RC, Lowman JT. A reliable method for evaluating drug compliance in children with cancer. Cancer 1979; 43: 169–173
- Zimm S, Collins JM, Riccardi R, et al. Variable bioavailability of oral mercaptopurine: is maintenance chemotherapy is acute lymphoblastic leukaemia being optimally delivered?. N Engl J Med. 1983; 308: 1005–1009
- Lennard L, Lilleyman JS. Are children with lymphoblastic leukaemia given enough 6-mercaptopurine?. Lancet 1987; ii: 785–787
- Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980; 32: 651–662
- Lennard L, Rees CA, Lilleyman JS, Maddocks JL. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol. 1983; 16: 359–363
- Endersen L, Lie SO, Storm-Mathieson I, Rugstad HE, Stokke O. Pharmacokinetics of oral 6-mercaptopurine: relationship between plasma levels and urine excretion of parent drug. Therapeutic Drug Monitoring 1990; 12: 227–234
- Hale JP, Lilleyman JS. Importance of 6-mercaptopurine dose in lymphoblastic leukaemia. Arch Dis Child. 1991; 66: 462–466
- Schmiegelow K, Pulczynska MK, Seip M. White cell count during maintenance chemotherapy for standard-risk childhood acute lymphoblastic leukaemia. Pediatr Hematol Oncol. 1988; 5: 259–267
- Dolan G, Lilleyman JS, Richards SM. Prognostic importance of myelosuppression during maintenance treatment of lymphoblastic leukaemia. Arch Dis Child. 1989; 64: 1231–1234
- van Eys J, Berry D, Crist W, et al. Treatment intensity and outcome for children with acute lymphocytic leukemia of standard risk; a Pediatric Oncology Group Study. Cancer 1989; 63: 1466–1471
- Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukaemia. J Clin Oncol. 1989; 7: 1816–1823
- Schwenn MR, Blattner SR, Lynch E, Weinstein HJ. HiC-COM: a 2 month intensive chemotherapy regimen for children with stage HI and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia. J Clin Oncol. 1991; 9: 133–138